Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products... Show more
Matinas BioPharma Holdings, Inc. is a clinical-stage biotechnology company focused on improving how medicines are delivered into the body. It is best known for its lipid nanocrystal (LNC) platform, a drug-delivery technology designed to administer treatments — including those that traditionally require intravenous or inhaled delivery — in oral or other convenient forms. Because the company is still in the research and development phase, its business profile and financial profile are shaped by pipeline progress, partnership activity, and financing rather than by product sales.
Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is headquartered in Bedminster, New Jersey. Its common stock trades on the NYSE American exchange under the ticker symbol MTNB. The company operates in the healthcare sector, specifically within the biotechnology industry, and maintains a small workforce consistent with its clinical-stage status.
The company's core asset is its lipid nanocrystal (LNC) platform technology. LNCs are engineered, lipid-based particles designed to encapsulate and deliver a wide range of therapeutic molecules — including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides — into cells safely and effectively. The platform's supporters argue that it offers potential advantages over other delivery approaches, such as lipid nanoparticles and viral vectors, particularly in enabling oral administration of drugs that currently require injection or infusion.
Like many clinical-stage biotechs, Matinas does not yet market any approved drug, so it has historically reported little or no product revenue. Its operations are funded through a combination of equity offerings, research grants, and, potentially, partnership or licensing agreements. The company's long-term business model centers on advancing its pipeline candidates through clinical trials and, if successful, either commercializing them directly or monetizing them through collaborations and licensing deals with larger pharmaceutical companies.
The company's lead product candidate is MAT2203, an oral formulation of amphotericin B, a well-established antifungal agent. MAT2203 has been studied for the treatment of invasive fungal infections such as aspergillosis and cryptococcal meningitis, and for the prevention of fungal infections in immunocompromised patients. A second candidate, MAT2501, is an orally administered formulation of the antibiotic amikacin. These programs illustrate the platform's goal of converting IV-only drugs into oral treatments.
Matinas operates in the highly competitive field of drug-delivery technology and anti-infective therapeutics. Its market position rests on the differentiation of its LNC platform rather than on scale. The company competes against larger biotechnology and pharmaceutical firms, as well as other delivery-technology developers, in areas such as antifungal and antibacterial treatments and nucleic-acid delivery. Its addressable markets include patients with difficult-to-treat invasive fungal infections, where oral alternatives to intravenous therapy could improve convenience and access.
Investors should note that the company's strategic direction has evolved. In recent periods, Matinas announced strategic transactions, including a planned business combination intended to repurpose the publicly listed entity toward clean energy and critical minerals, as well as an agreement to divest its LNC platform technology and lead candidate MAT2203. Such corporate actions reflect the fluid, capital-intensive nature of early-stage biotech operations and can materially change the company's future profile.
Investors follow MTNB primarily for the potential of its delivery technology and pipeline. The LNC platform's ability to enable oral administration of drugs that currently require injection or infusion represents a meaningful, if unproven, value proposition. Additionally, the company's work in invasive fungal infections addresses a serious medical need, particularly among immunocompromised patients. For risk-tolerant investors, the appeal lies in the possibility that a clinical or partnership milestone could unlock significant value.
Matinas carries risks typical of clinical-stage biotechnology companies. It has no approved products and limited revenue, which creates ongoing needs for capital that can lead to shareholder dilution. Clinical trials may fail or be delayed, and regulatory approval is never guaranteed. The company also faces intense competition, a small workforce, and dependence on strategic partnerships and financing to continue operations. Its evolving corporate strategy — including announced transactions and changes in strategic focus — adds further uncertainty. Prospective investors should review the company's SEC filings, including its most recent annual and quarterly reports, for a complete picture of its financial condition and going-concern considerations.
For investors seeking to research companies like MTNB alongside thousands of other opportunities, Tickeron's AI Screener offers an AI-powered discovery platform for stocks and ETFs. It enables users to filter securities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, and price patterns. Rather than reviewing tickers one at a time, traders can efficiently screen the broader market to surface ideas that align with their own investment strategies and criteria.
Matinas BioPharma Holdings (MTNB) is a clinical-stage biotechnology company whose identity is built around its lipid nanocrystal delivery platform and its pipeline of oral anti-infective candidates. Its relevance to investors stems from the potential of that technology and its ability to attract strategic interest, balanced against the substantial risks of an early-stage, capital-intensive business with no approved products. As with any development-stage biotech, understanding its technology, financing needs, and evolving corporate strategy is essential before forming any investment view.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a manufacturer of pharmaceutical products
Industry Biotechnology